Daiichi Sankyo Company, Limited (TYO:4568)
2,703.00
+2.50 (0.09%)
May 26, 2026, 2:35 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
107.41M JPY
Profits / Employee
13.15M JPY
Market Cap
4.91T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Astellas Pharma | 13,643 |
| Kyowa Kirin | 5,161 |
| Chugai Pharmaceutical | 5,104 |
| Ono Pharmaceutical | 4,287 |
| Santen Pharmaceutical | 3,849 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Daiichi Sankyo Company News
- 3 days ago - FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer - Nasdaq
- 7 days ago - Full Year 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 7 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA Approval In Two Early Breast Cancer Indications - Nasdaq
- 8 days ago - AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings - Nasdaq
- 14 days ago - Daiichi Sankyo Company Earnings Call Transcript: Q4 2026 - Transcripts
- 14 days ago - Daiichi Sankyo Company Quarterly report: Q4 2026 - Filings
- 14 days ago - Daiichi Sankyo Company Slides: Q4 2026 - Filings
- 14 days ago - Daiichi Sankyo Company Earnings Call Transcript: Q4 2026 - Transcripts